Q2 2024 EPS Estimates for Kiniksa Pharmaceuticals, Ltd. Lifted by Wedbush (NASDAQ:KNSA)

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) – Equities researchers at Wedbush lifted their Q2 2024 EPS estimates for Kiniksa Pharmaceuticals in a research note issued to investors on Tuesday, April 23rd. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per share of ($0.06) for the quarter, up from their previous estimate of ($0.16). Wedbush currently has a “Outperform” rating and a $30.00 target price on the stock. The consensus estimate for Kiniksa Pharmaceuticals’ current full-year earnings is ($0.06) per share. Wedbush also issued estimates for Kiniksa Pharmaceuticals’ Q3 2024 earnings at ($0.02) EPS, Q4 2024 earnings at $0.01 EPS, FY2024 earnings at ($0.32) EPS, Q1 2025 earnings at $0.02 EPS, Q2 2025 earnings at $0.03 EPS, Q3 2025 earnings at $0.07 EPS, Q4 2025 earnings at $0.12 EPS, FY2025 earnings at $0.24 EPS, FY2026 earnings at $0.80 EPS and FY2027 earnings at $1.26 EPS.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, April 23rd. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.11). The firm had revenue of $79.90 million during the quarter, compared to the consensus estimate of $76.97 million. Kiniksa Pharmaceuticals had a net margin of 2.78% and a negative return on equity of 7.32%. The business’s revenue was up 65.4% compared to the same quarter last year. During the same period last year, the business earned ($0.18) earnings per share.

A number of other analysts have also recently weighed in on KNSA. TheStreet raised shares of Kiniksa Pharmaceuticals from a “d+” rating to a “c” rating in a research note on Thursday, February 29th. Evercore ISI lifted their price target on shares of Kiniksa Pharmaceuticals from $25.00 to $30.00 and gave the stock an “outperform” rating in a report on Wednesday.

Kiniksa Pharmaceuticals Price Performance

Shares of NASDAQ:KNSA opened at $17.61 on Thursday. The company’s 50 day simple moving average is $19.32 and its 200 day simple moving average is $18.00. The stock has a market capitalization of $1.24 billion, a price-to-earnings ratio of 160.11 and a beta of 0.27. Kiniksa Pharmaceuticals has a 1 year low of $10.65 and a 1 year high of $22.09.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals news, CAO Michael R. Megna sold 5,126 shares of the business’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $21.79, for a total value of $111,695.54. Following the transaction, the chief accounting officer now directly owns 17,588 shares in the company, valued at $383,242.52. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Kiniksa Pharmaceuticals news, CAO Michael R. Megna sold 5,126 shares of the business’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $21.79, for a total value of $111,695.54. Following the transaction, the chief accounting officer now directly owns 17,588 shares in the company, valued at $383,242.52. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Sanj K. Patel sold 5,582 shares of the company’s stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $21.00, for a total transaction of $117,222.00. Following the sale, the chief executive officer now owns 65,012 shares in the company, valued at $1,365,252. The disclosure for this sale can be found here. In the last ninety days, insiders sold 33,109 shares of company stock valued at $709,929. Corporate insiders own 54.23% of the company’s stock.

Institutional Trading of Kiniksa Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of KNSA. IFP Advisors Inc purchased a new stake in Kiniksa Pharmaceuticals in the 3rd quarter worth approximately $65,000. China Universal Asset Management Co. Ltd. lifted its stake in Kiniksa Pharmaceuticals by 349.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,097 shares of the company’s stock worth $72,000 after purchasing an additional 3,186 shares in the last quarter. Victory Capital Management Inc. purchased a new stake in Kiniksa Pharmaceuticals in the 3rd quarter worth approximately $176,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Kiniksa Pharmaceuticals in the 4th quarter worth $213,000. Finally, QRG Capital Management Inc. bought a new position in shares of Kiniksa Pharmaceuticals in the 3rd quarter worth $249,000. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.